Cargando…

Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention

Current oral antiretroviral agents provide highly effective treatment for patients infected with human immunodeficiency virus (HIV), and can be used as pre-exposure prophylaxis (PrEP) to prevent new HIV infections. Several single-tablet regimens with excellent antiviral efficacy have dramatically im...

Descripción completa

Detalles Bibliográficos
Autor principal: Kim, Yeon-Sook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8731252/
https://www.ncbi.nlm.nih.gov/pubmed/34979604
http://dx.doi.org/10.3947/ic.2021.0136
_version_ 1784627318383181824
author Kim, Yeon-Sook
author_facet Kim, Yeon-Sook
author_sort Kim, Yeon-Sook
collection PubMed
description Current oral antiretroviral agents provide highly effective treatment for patients infected with human immunodeficiency virus (HIV), and can be used as pre-exposure prophylaxis (PrEP) to prevent new HIV infections. Several single-tablet regimens with excellent antiviral efficacy have dramatically improved the quality of life of patients who can adhere to daily oral therapy. However, there is increasing demand on long-acting injectable antiretroviral agents for patients who cannot take oral agents or feel fatigue related to daily pill burden. Monthly long-acting (LA) cabotegravir (CAB) combined with rilpivirine (RPV) has recently been listed as optimizing agent for maintenance of HIV suppression in treatment-experienced patients whose viral load is undetectable for 3 to 6 months. Novel agents with different mechanism of action and long half-life extending dosing interval are being tested in phase 2 and 3 clinical trials. This review summarizes the data of efficacies and safety profiles of LA CAB with RPV regimen, and also new long-acting injectable antiretroviral agents in pipeline.
format Online
Article
Text
id pubmed-8731252
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS
record_format MEDLINE/PubMed
spelling pubmed-87312522022-01-13 Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention Kim, Yeon-Sook Infect Chemother Review Article Current oral antiretroviral agents provide highly effective treatment for patients infected with human immunodeficiency virus (HIV), and can be used as pre-exposure prophylaxis (PrEP) to prevent new HIV infections. Several single-tablet regimens with excellent antiviral efficacy have dramatically improved the quality of life of patients who can adhere to daily oral therapy. However, there is increasing demand on long-acting injectable antiretroviral agents for patients who cannot take oral agents or feel fatigue related to daily pill burden. Monthly long-acting (LA) cabotegravir (CAB) combined with rilpivirine (RPV) has recently been listed as optimizing agent for maintenance of HIV suppression in treatment-experienced patients whose viral load is undetectable for 3 to 6 months. Novel agents with different mechanism of action and long half-life extending dosing interval are being tested in phase 2 and 3 clinical trials. This review summarizes the data of efficacies and safety profiles of LA CAB with RPV regimen, and also new long-acting injectable antiretroviral agents in pipeline. The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2021-12 2021-12-20 /pmc/articles/PMC8731252/ /pubmed/34979604 http://dx.doi.org/10.3947/ic.2021.0136 Text en Copyright © 2021 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kim, Yeon-Sook
Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention
title Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention
title_full Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention
title_fullStr Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention
title_full_unstemmed Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention
title_short Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention
title_sort long-acting injectable antiretroviral agents for hiv treatment and prevention
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8731252/
https://www.ncbi.nlm.nih.gov/pubmed/34979604
http://dx.doi.org/10.3947/ic.2021.0136
work_keys_str_mv AT kimyeonsook longactinginjectableantiretroviralagentsforhivtreatmentandprevention